214 related articles for article (PubMed ID: 21375480)
81. Newer antidepressants go beyond serotonin--and the synapse.
Dolgin E
Nat Med; 2010 Dec; 16(12):1345. PubMed ID: 21135817
[No Abstract] [Full Text] [Related]
82. Neurobiology of depression and novel antidepressant drug targets.
Kern N; Sheldrick AJ; Schmidt FM; Minkwitz J
Curr Pharm Des; 2012; 18(36):5791-801. PubMed ID: 22681160
[TBL] [Abstract][Full Text] [Related]
83. Potential targets for the development of novel antidepressants: future perspectives.
Thakare VN; Patel BM
CNS Neurol Disord Drug Targets; 2015; 14(2):270-81. PubMed ID: 25106638
[TBL] [Abstract][Full Text] [Related]
84. Drug Targets for Obesity and Depression: From Serotonin to Leptin.
Haleem DJ
Curr Drug Targets; 2016; 17(11):1282-91. PubMed ID: 26648065
[TBL] [Abstract][Full Text] [Related]
85. Neurogenesis and Neuroplasticity in Major Depression: Its Therapeutic Implication.
Bourin M
Adv Exp Med Biol; 2021; 1305():157-173. PubMed ID: 33834400
[TBL] [Abstract][Full Text] [Related]
86. Plasticity of synapses and reward circuit function in the genesis and treatment of depression.
Thompson SM
Neuropsychopharmacology; 2023 Jan; 48(1):90-103. PubMed ID: 36057649
[TBL] [Abstract][Full Text] [Related]
87. Neuroplasticity and major depression, the role of modern antidepressant drugs.
Serafini G
World J Psychiatry; 2012 Jun; 2(3):49-57. PubMed ID: 24175168
[TBL] [Abstract][Full Text] [Related]
88. Brain neurotoxic amyloid-beta peptides: their potential role in the pathophysiology of depression and as molecular therapeutic targets.
Pomara N; Sidtis JJ
Br J Pharmacol; 2010 Oct; 161(4):768-70. PubMed ID: 21105218
[TBL] [Abstract][Full Text] [Related]
89. Cellular plasticity and resilience and the pathophysiology of severe mood disorders.
Charney DS; Dejesus G; Manji HK
Dialogues Clin Neurosci; 2004 Jun; 6(2):217-25. PubMed ID: 22033657
[TBL] [Abstract][Full Text] [Related]
90. Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder.
Niciu MJ; Ionescu DF; Mathews DC; Richards EM; Zarate CA
CNS Spectr; 2013 Oct; 18(5):231-41. PubMed ID: 23462230
[TBL] [Abstract][Full Text] [Related]
91. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity.
Artin H; Zisook S; Ramanathan D
World J Psychiatry; 2021 Jun; 11(6):201-214. PubMed ID: 34168967
[TBL] [Abstract][Full Text] [Related]
92. Unlocking Therapeutic Synergy: Tailoring Drugs for Comorbidities such as Depression and Diabetes through Identical Molecular Targets in Different Cell Types.
Coppola T; Daziano G; Legroux I; Béraud-Dufour S; Blondeau N; Lebrun P
Cells; 2023 Dec; 12(23):. PubMed ID: 38067196
[TBL] [Abstract][Full Text] [Related]
93. Mechanisms underlying the neuroprotective effect of brain reserve against late life depression.
Freret T; Gaudreau P; Schumann-Bard P; Billard JM; Popa-Wagner A
J Neural Transm (Vienna); 2015 Aug; 122 Suppl 1():S55-61. PubMed ID: 24390152
[TBL] [Abstract][Full Text] [Related]
94. Depression pathogenesis and treatment: what can we learn from blood mRNA expression?
Hepgul N; Cattaneo A; Zunszain PA; Pariante CM
BMC Med; 2013 Feb; 11():28. PubMed ID: 23384232
[TBL] [Abstract][Full Text] [Related]
95. Common mechanisms of pain and depression: are antidepressants also analgesics?
Nekovarova T; Yamamotova A; Vales K; Stuchlik A; Fricova J; Rokyta R
Front Behav Neurosci; 2014; 8():99. PubMed ID: 24723864
[TBL] [Abstract][Full Text] [Related]
96. Clinical Translation of 5-HT
Frokjaer VG
Biol Psychiatry Cogn Neurosci Neuroimaging; 2023 Nov; 8(11):1068-1069. PubMed ID: 37940224
[No Abstract] [Full Text] [Related]
97. Towards a multimodal treatment of depression: a minireview on the potential role of antibiotics.
Yulug B; Schäbitz WR
Mini Rev Med Chem; 2011 Oct; 11(11):984-7. PubMed ID: 21762101
[TBL] [Abstract][Full Text] [Related]
98. Editorial: The glutamate hypothesis of mood disorders: Neuroplasticity processes, clinical features, treatment perspectives.
Guglielmo R; de Filippis R; Ouanes S; Hasler G
Front Psychiatry; 2022; 13():1054887. PubMed ID: 36523869
[No Abstract] [Full Text] [Related]
99. A human translational model based on neuroplasticity for pharmacological agents potentially effective in Treatment-Resistant Depression: focus on dopaminergic system.
Collo G; Merlo Pich E
Neural Regen Res; 2020 Jun; 15(6):1027-1029. PubMed ID: 31823876
[No Abstract] [Full Text] [Related]
100. FAAH Inhibition Restores Early Life Stress-Induced Alterations in PFC microRNAs Associated with Depressive-Like Behavior in Male and Female Rats.
Portugalov A; Zaidan H; Gaisler-Salomon I; Hillard CJ; Akirav I
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
